Biorasi is a full-service global CRO, experienced and engaged in the management of multiple coronavirus clinical trials. For companies ready to start up and initiate on potential opportunities to develop interventions and treatments for COVID-19, we are ready for action.
The current heath emergency caused by the pandemic has placed health systems around the world under extreme pressure. One of the biggest challenges that the industry faces is overcoming the inexperience of handling such a grave condition, one with few common symptoms.
Biorasi Kicks-Off Third COVID-19 Clinical Trial for 2020
Biorasi has met the First Patient, First Visit milestone for a dermatology trial across multiple sites during the COVID-19 pandemic.
Biorasi is proud to announce the appointment of Scott Nenninger to the position of Chief Financial Officer (CFO)
Biorasi has completed subject visits under Part A in a rare disease nephropathy study during the peak of the COVID-19 outbreak.
Biorasi is proud to announce the start of a second COVID-19 clinical trial for 2020. The trial will be executed in Russia and Ukraine and will focus on the efficacy of prophylaxis medication for maintaining the health and safety of healthcare personnel treating patients with the coronavirus.
The Biorasi Project Team were focused on the completion of two critical project milestones which were suddenly put at risk due to the COVID-19 health crisis. Find out how the team were able to keep the project on track in our latest case study.
Biorasi is proud to announce the initiation of the company’s first COVID-19 clinical trial in May 2020. The U.S.-based trial will focus on the treatment for lung injuries caused by the COVID-19 virus.
Dr. Kurt Gehlsen, Chief Scientific Officer and Vice President of Medical and Scientific Affairs, has been appointed to the COVID-19 Rapid Response Funding panel at Science Foundation Ireland (SFI).
To our #sitepartners on the front lines, from all of us at Biorasi, thank you for everything you do to bring critical treatments to patients as we face #COVID19 together.
In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital. Without a proactive and comprehensive strategy in place to manage clinical trials over the coming weeks and maybe months, consequences may be severe –especially for those that need the treatment the most.
